(Total Views: 402)
Posted On: 02/02/2021 9:57:40 AM
Post# of 8470
Release #:812-198018-rl-799272:
OWN SNAP
Bioelectronics (BIEL) Moves Up On High Volume: Now What?
February 1, 2021 By Michael Rowels
If you are looking to get into stocks that have been displaying considerable momentum then it might be a good idea to track the Bioelectronics Corp (OTC: BIEL) stock.
The stock has displayed strong momentum in recent days and over the course of the last week, it managed to deliver gains of as much as 50%. The trigger for the rally in BioElectronics might have been the announcement of the company’s fourth-quarter results back on January 19.
BioElectronics managed to generate revenues of $519,000 in the quarter, which represents a massive jump of as high as 241% from the previous quarter.
The revenues stood at $152,000 in the third quarter. However, more importantly, the company announced that on top of the revenues it generated, there are going to be deferred revenues to the tune of $554,000. Lastly, the two biggest lenders to BioElectronics have also decided to forego interest payments totaling as much as $750,000 in 2020 and are going to do the same in 2021.
Michael Rowels
Writing for business and finance publishers has become his passion over the last decades after he completed a master’s degree in Financial Management. Sharing some opinions and forecasts to thousands of readers is a routine job for him but he never promises to invest in one stock.
2/2/2021 8:39:41 AM
OWN SNAP
Bioelectronics (BIEL) Moves Up On High Volume: Now What?
February 1, 2021 By Michael Rowels
If you are looking to get into stocks that have been displaying considerable momentum then it might be a good idea to track the Bioelectronics Corp (OTC: BIEL) stock.
The stock has displayed strong momentum in recent days and over the course of the last week, it managed to deliver gains of as much as 50%. The trigger for the rally in BioElectronics might have been the announcement of the company’s fourth-quarter results back on January 19.
BioElectronics managed to generate revenues of $519,000 in the quarter, which represents a massive jump of as high as 241% from the previous quarter.
The revenues stood at $152,000 in the third quarter. However, more importantly, the company announced that on top of the revenues it generated, there are going to be deferred revenues to the tune of $554,000. Lastly, the two biggest lenders to BioElectronics have also decided to forego interest payments totaling as much as $750,000 in 2020 and are going to do the same in 2021.
Michael Rowels
Writing for business and finance publishers has become his passion over the last decades after he completed a master’s degree in Financial Management. Sharing some opinions and forecasts to thousands of readers is a routine job for him but he never promises to invest in one stock.
2/2/2021 8:39:41 AM
(2)
(1)
